Literature DB >> 33469992

Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future.

Alfred I Neugut1, Susan E Bates1.   

Abstract

Entities:  

Year:  2021        PMID： 33469992      PMCID： PMC8018296          DOI： 10.1002/onco.13681

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  19 in total

Review 1.  The latest consensus on antiemetics.

Authors:  Jørn Herrstedt
Journal:  Curr Opin Oncol       Date:  2018-07       Impact factor: 3.645

2.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Authors:  F Roila; A Molassiotis; J Herrstedt; M Aapro; R J Gralla; E Bruera; R A Clark-Snow; L L Dupuis; L H Einhorn; P Feyer; P J Hesketh; K Jordan; I Olver; B L Rapoport; J Roscoe; C H Ruhlmann; D Walsh; D Warr; M van der Wetering
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

3.  Immuno-oncology drug development forges on despite COVID-19.

Authors:  Samik Upadhaya; Vanessa M Hubbard-Lucey; Jia Xin Yu
Journal:  Nat Rev Drug Discov       Date:  2020-11       Impact factor: 84.694

4.  The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Authors:  M Aapro; A Molassiotis; M Dicato; I Peláez; Á Rodríguez-Lescure; D Pastorelli; L Ma; T Burke; A Gu; P Gascon; F Roila
Journal:  Ann Oncol       Date:  2012-03-06       Impact factor: 32.976

5.  What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.

Authors:  Eric J Roeland; Kathryn J Ruddy; Thomas W LeBlanc; Ryan D Nipp; Gary Binder; Silvia Sebastiani; Ravi Potluri; Luke Schmerold; Eros Papademetriou; Lee Schwartzberg; Rudolph M Navari
Journal:  J Natl Compr Canc Netw       Date:  2020-06       Impact factor: 11.908

6.  Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

Authors:  D Campos; J R Pereira; R R Reinhardt; C Carracedo; S Poli; C Vogel; J Martinez-Cedillo; A Erazo; J Wittreich; L O Eriksson; A D Carides; B J Gertz
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.

Authors:  Alexander Molassiotis; Matti Aapro; Mario Dicato; Pere Gascon; Sylvia A Novoa; Nicolas Isambert; Thomas A Burke; Anna Gu; Fausto Roila
Journal:  J Pain Symptom Manage       Date:  2013-09-24       Impact factor: 3.612

Review 8.  Best Practices for Reducing Unplanned Acute Care for Patients With Cancer.

Authors:  Nathan R Handley; Lynn M Schuchter; Justin E Bekelman
Journal:  J Oncol Pract       Date:  2018-04-17       Impact factor: 3.840

9.  Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.

Authors:  Nirosha Mahendraratnam; Joel F Farley; Ethan Basch; Amber Proctor; Stephanie B Wheeler; Stacie B Dusetzina
Journal:  Support Care Cancer       Date:  2019-03-26       Impact factor: 3.603

10.  Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Hironobu Hashimoto; Masakazu Abe; Osamu Tokuyama; Hideaki Mizutani; Yosuke Uchitomi; Takuhiro Yamaguchi; Yukari Hoshina; Yasuhiko Sakata; Takako Yanai Takahashi; Kazuhisa Nakashima; Masahiko Nakao; Daisuke Takei; Sadamoto Zenda; Koki Mizukami; Satoru Iwasa; Michiru Sakurai; Noboru Yamamoto; Yuichiro Ohe
Journal:  Lancet Oncol       Date:  2019-12-11       Impact factor: 41.316
View more
  2 in total

1.  Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.

Authors:  Tobias Janowitz; Sam Kleeman; Robert H Vonderheide
Journal:  Oncologist       Date:  2021-02-26

Review 2.  Cancer-related emergency and urgent care: expanding the research agenda.

Authors:  Nonniekaye Shelburne; Naoko Ishibe Simonds; Roxanne E Jensen; Jeremy Brown
Journal:  Emerg Cancer Care       Date:  2022-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.